Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke

Inclusion Criteria: * Age≥35 years and \<80 years; * Diagnosis of ischemic stroke in recovery phase, according to the Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2010; * Diagnosis of ischemic stroke with qi deficiency and blood stasis syndrome; * The interval from the onset to recruitment was 15-28 days; * FM score \<90 or AQ\<93.8 and diagnosis of aphasia; * Diagnosis of cerebral anterior circulation obstruction; * 4≤ NIHSS score\<20; * Patient is willing to participate voluntarily and to sign a written patient informed consent. Exclusion Criteria: * Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.) on CT or MRI. * Known history of allergy or suspected allergic to the study drugs. * Liver function impairment with the value of ALT or AST over 1.5-fold of normal value. * Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value. * Cerebral embolism caused by cerebral tumor, cerebral trauma, cerebral parasitosis, rheumatic heart disease, coronary heart disease or other cardiac diseases complicated with atrial fibrillation. * Prestroke score on the mRS ≥2. * Space-occupying lesions, CT or MRI revealed midline structure shift; CT revealed that massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery. * Disable patients prescribed by law（blind, deaf, dumb, mental retardation, mental disorders and physical disabilities which due to other causes affect neural function deficient scale). * Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months. * Suspected addicted into alcohol or drug abuse; with severe complications that would make the condition more complicated assessed by the investigator. * Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent. * Patient who is participating in other trials or has been participated in other trials in recent 3 months.